Needham Maintains Buy on Selecta Biosciences, Lowers Price Target to $6
Needham analyst Gil Blum maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $7 to $6.
Selecta Biosciences Q1 EPS $0.08 Up From $(0.22) YoY
Selecta Biosciences (NASDAQ:SELB) reported quarterly earnings of $0.08 per share. This is a 136.36 percent increase over losses of $(0.22) per share from the same period last year.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Earnings Outlook For Selecta Biosciences
Selecta Biosciences (NASDAQ:SELB) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Selecta Biosciences will report an earnings per share (EPS) of $-0.11.
Selecta Biosciences Announces Six Presentations At The Upcoming 25th Annual Meeting Of The American Society Of Gene & Cell Therapy
Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, power gene therapies and mitigate
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
